×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Press Release

View printer-friendly version
Amgen's Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
2012 Total Revenues and Adjusted EPS Guidance Ranges Increased to $16.9-$17.2 Billion and $6.20-$6.35
Second Quarter 2012 GAAP EPS Increased 29 Percent to $1.61

THOUSAND OAKS, Calif., July 26, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2012.  Key results for the quarter include:

  • Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfolio.
  • Amgen modified its agreement with Takeda to grant exclusive worldwide development rights for motesanib, recognizing income of $206 million in other revenues.
  • Adjusted EPS grew 34 percent to $1.83 due to 23 percent adjusted operating income growth and lower shares outstanding.  Adjusted net income increased 12 percent to $1,433 million.
  • GAAP EPS increased 29 percent to $1.61 and GAAP net income increased 8 percent to $1,266 million.
  • Amgen generated approximately $2.2 billion of free cash flow.
  • Four AMG 145 Phase 2 studies have successfully completed and the Company plans to initiate Phase 3 development in early 2013.

"I am very pleased with the performance of the business in the first half," said Bob Bradway, CEO at Amgen. "I am excited about the growth opportunities in our research and development pipeline, particularly our biologic AMG 145 for hypercholesterolemia."



Year-Over-Year (YOY)

$Millions, except EPS and percentages


Q2 '12


Q2 '11


YOY








Total Revenue


$4,477


$3,959


13%

Adjusted Net Income


1,433


1,281


12%

Adjusted EPS


1.83


1.37


34%








GAAP Net Income


1,266


1,170


8%

GAAP EPS


$1.61


$1.25


29%

Adjusted EPS, adjusted operating income, adjusted net income, and free cash flow are non-GAAP financial measures.  These adjustments and other items are presented on the attached reconciliations.  

Product Sales Performance

  • Total product sales increased 8 percent driven by strong commercial execution across the portfolio.
  • Combined Neulasta® (pegfilgrastim) and NEUPOGEN® (Filgrastim) sales grew 2 percent driven mainly by an increase in the U.S. average net sales price.
    • Combined U.S. Neulasta and NEUPOGEN sales increased 6 percent driven by increases in the average net sales price and unit demand, offset partially by a decrease in wholesaler inventories.
    • Combined Neulasta and NEUPOGEN sales in the rest of the world (ROW) declined 13 percent due to a decrease in NEUPOGEN unit demand from loss of share to biosimilars and a decrease in the average net sales price of Neulasta and NEUPOGEN.
  • Enbrel® (etanercept) sales increased 11 percent driven primarily by an increase in the average net sales price, as well as increases in unit demand and wholesaler inventories.
  • Aranesp® (darbepoetin alfa) sales decreased 8 percent driven primarily by a decline in unit demand. 
    • U.S. sales decreased 11 percent driven primarily by a decline in unit demand, offset partially by a change in accounting estimates and an increase in the average net sales price.
    • ROW sales decreased 7 percent driven primarily by a decrease in the average net sales price.
  • EPOGEN® (epoetin alfa) sales decreased 3 percent driven by a reduction in dose utilization, offset largely by reductions in customer discounts and a change in accounting estimates.
    • On a sequential basis, EPOGEN sales increased 18 percent driven by customer and wholesaler buying patterns.  There was a low single-digit percentage point growth in underlying unit demand.
  • Growth-phase products: Sensipar®/Mimpara® (cinacalcet), Vectibix® (panitumumab), and Nplate® (romiplostim) increased 15 percent driven by higher unit demand.
  • Momentum for both XGEVA® (denosumab) and Prolia® (denosumab) continued in the second quarter with solid sequential growth.
    • XGEVA sales increased 17 percent on a sequential basis, reflecting increased segment share as well as growth in the overall skeletal-related events segment.
    • Prolia sales increased 36 percent on a sequential basis, reflecting continued unit growth globally.

Product Sales Detail by Product and Geographic Region









$Millions, except percentages


Q2 '12


Q2 '11


YOY



US

ROW

TOTAL


TOTAL


TOTAL










Neulasta®/ NEUPOGEN®


$1,062

$285

$1,347


$1,326


2%

Neulasta®


794

221

1,015


1,015


0%

NEUPOGEN®


268

64

332


311


7%

Enbrel®


991

67

1,058


956


11%

Aranesp®


215

321

536


585


(8%)

EPOGEN®


525

0

525


543


(3%)

Sensipar® / Mimpara®


150

82

232


199


17%

Vectibix®


31

59

90


81


11%

Nplate®


50

36

86


75


15%

XGEVA®


156

23

179


73


*

Prolia®


75

45

120


44


*

Other 


0

27

27


11


*










Total product sales


$3,255

$945

$4,200


$3,893


8%










* Not meaningful









Other Revenues

  • Other revenues increased to $277 million in the second quarter of 2012 versus $66 million in the second quarter of 2011, driven by changes to the Company's motesanib collaboration with Takeda Pharmaceutical Company Limited.  As part of efforts to focus its research and development (R&D) activities, in the second quarter, the Company replaced the global co-development and profit share agreement with an exclusive license for Takeda to develop, manufacture and commercialize motesanib.  This resulted in revenue recognition of $206 million from an upfront payment received from Takeda when the collaboration was originally formed in 2008.

Operating Expense and Tax Rate Analysis, on an Adjusted Basis

  • Cost of Sales, excluding the impact of the Puerto Rico excise tax, increased 0.4 points to 13.9 percent of sales driven primarily by product mix, offset partially by higher average net sales prices and lower royalties.
  • R&D expenses were flat.  Expenses in support of our later-stage clinical programs increased, driven by AMG 145 and AMG 785.  This increase was offset by reduced expenses associated with marketed product support and Discovery Research and Translational Sciences.
  • Selling, General & Administrative (SG&A) expenses increased 8 percent driven primarily by international expansion as well as higher ENBREL profit share expenses.
    • ENBREL profit share expenses increased 11 percent to $371 million in the second quarter.  

$Millions, except percentages







On an Adjusted Basis


Q2 '12


Q2 '11


YOY










Cost of Sales

$668


$569


17%


% of sales


15.9%


14.6%


1.3 pts


% of sales (Excluding PR excise tax)


13.9%


13.5%


0.4 pts

Research & Development (R&D)

$807


$808


0%


% of sales


19.2%


20.8%


(1.6) pts

Selling, General & Administrative (SG&A)

$1,199


$1,111


8%


% of sales


28.5%


28.5%


0 pts

TOTAL Operating Expenses

$2,674


$2,488


7%










pts: percentage points

 







  • Tax Rate increased by 0.8 points to 16.0 percent due primarily to the expiry of the U.S. federal R&D tax credit at the end of 2011.  As of June 30, 2012, the R&D tax credit had not been extended. 

On an Adjusted Basis


Q2 '12


Q2 '11


YOY










Tax Rate

16.0%


15.2%


0.8 pts

Tax Rate (Excluding PR excise tax)

20.6%


20.3%


0.3 pts










pts: percentage points







Cash Flow and Balance Sheet Discussion

  • The Company generated $2.2 billion of free cash flow in the quarter versus $1.4 billion in the second quarter of 2011. The increase was primarily driven by the termination of fixed to floating interest rate swap agreements that resulted in receipt of $0.4 billion in cash, and by the collection of $0.2 billion of outstanding trade receivables in Spain. The termination of the swap agreements will be recognized as a reduction of interest expense over the remaining term of the underlying contracts and did not materially impact income in the quarter. 
  • During the quarter, Amgen repurchased approximately 17 million shares of common stock at a total cost of $1.2 billion at an average price of $69.31.  This brings the total shares repurchased under its $10 billion authorized stock repurchase program to 122 million at a total cost of $7.6 billion at an average price of $62.75.
  • During the quarter, the Company raised an additional $3 billion in U.S. bonds with an average maturity of 15 years and an average pre-tax coupon of 3.6 percent, and now has adequate funding to complete its $10 billion share repurchase program.
  • The Company previously announced that its Board of Directors declared a $0.36 per share dividend for the third quarter of 2012. The dividend will be paid on Sept. 7, 2012, to all stockholders of record as of the close of business on Aug. 16, 2012.

 

$Billions, except shares


Q2 '12


Q2 '11


YOY










Operating Cash Flow

$2.4


$1.5


$0.9

Capital Expenditures

0.2


0.1


0.1

Free Cash Flow

2.2


1.4


0.8

Dividend Paid

0.3


0.0


0.3

Cost of Shares Repurchased

1.2


0.7


0.5

Adjusted Avg. Diluted Shares (millions)

784


934


(150)










Cash Balance

22.5


19.2


3.3

Adjusted Debt Outstanding

24.5


14.2


10.3

Stockholders' Equity

19.2


25.6


(6.4)

2012 Guidance

For the full year 2012, the Company now expects:

  • Total revenues to be in the range of $16.9 billion to $17.2 billion and adjusted EPS to be in the range of $6.20 to $6.35.

The Company continues to expect:

  • Adjusted tax rate to be in the range of 14 percent to 15 percent.  Excluding the Puerto Rico excise tax, Amgen still expects the adjusted tax rate for 2012 to be in the range of 19 percent to 20 percent.
  • Capital expenditures to be approximately $700 million.

Second Quarter Pipeline Update

The Company provided the following information on selected clinical programs:

  • AMG 145: The Company announced that in four Phase 2 studies (evaluating AMG 145 as monotherapy, in combination with statin therapy, in heterozygous familial hypercholesterolemia, and in statin-intolerant subjects), treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol. Based on the Phase 2 efficacy and safety data, the Company plans to initiate Phase 3 development in early 2013.
  • Rilotumumab (AMG 102): The Company discussed Phase 2 data showing that the addition of rilotumumab to chemotherapy improved median overall survival in subjects with gastric tumors with high expression of the hepatocyte growth factor receptor, MET. Phase 3 planning is underway.
  • AMG 785: The Company stated that it was enrolling a second Phase 3 study (alendronate-controlled) to evaluate safety and efficacy of AMG 785 in women with postmenopausal osteoporosis.
  • KAI Pharmaceuticals: The Company discussed the completion of the acquisition of KAI Pharmaceuticals on July 5, 2012. Phase 3 planning is underway for the lead molecule, KAI-4169.

Non-GAAP Financial Measures

The Adjusted non-GAAP (U.S. Generally Accepted Accounting Principles) financial measures included above for the second quarters of 2012 and 2011 exclude, for the applicable periods, certain expenses related to acquisitions and cost-savings initiatives, non-cash interest expense associated with our convertible notes and certain other adjustments, as applicable. These adjustments and other items are presented on the attached reconciliations.

Management has presented its operating results in accordance with GAAP and on an "adjusted" (or non-GAAP) basis for the second quarters of 2012 and 2011. In addition, management has presented its outstanding debt in accordance with GAAP and on an "adjusted" (or non-GAAP) basis as of June 30, 2012 and 2011.  The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors.  The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning.  These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit http://www.amgen.com/.  Follow us on http://twitter.com/#!/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K.  Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. 

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products.  In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.  We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.  Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.  Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

 

Amgen Inc.

Condensed Consolidated Statements of Income - GAAP

(In millions, except per share data)

(Unaudited)














Three months ended


Six months ended 




June 30, 


June 30, 




2012


2011


2012


2011

Revenues:









Product sales

$  4,200


$  3,893


$  8,101


$  7,511


Other revenues

277


66


424


154



Total revenues

4,477


3,959


8,525


7,665











Operating expenses:









Cost of sales (excludes amortization of certain










acquired intangible assets presented below)

682


602


1,361


1,166


Research and development

826


819


1,562


1,555


Selling, general and administrative

1,228


1,130


2,304


2,153


Amortization of certain acquired intangible assets

73


73


147


147


Other

79


3


85


19



Total operating expenses

2,888


2,627


5,459


5,040











Operating income

1,589


1,332


3,066


2,625











Interest expense, net

256


122


491


257

Interest and other income, net

124


129


248


277











Income before income taxes

1,457


1,339


2,823


2,645











Provision for income taxes

191


169


373


350











Net income

$  1,266


$  1,170


$  2,450


$  2,295











Earnings per share:









Basic

$    1.63


$    1.26


$    3.13


$    2.47


Diluted

$    1.61


$    1.25


$    3.09


$    2.45











Average shares used in calculation









of earnings per share:









Basic

776


927


783


930


Diluted

785


935


792


938

 

 

Amgen Inc.

Product Sales Detail by Product and Geographic Region




(In millions)

(Unaudited)





















Three months ended


Six months ended 



June 30, 


June 30, 



2012


2011


2012


2011










Neulasta®- U.S.

$     794


$     769


$  1,608


$  1,479










NEUPOGEN®- U.S.

268


230


507


450










Neulasta®- ROW

221


246


446


472










NEUPOGEN®- ROW

64


81


130


157










Enbrel®- U.S.

991


894


1,869


1,715










Enbrel®- Canada

67


62


127


116










Aranesp®- U.S.

215


241


417


491










Aranesp®- ROW

321


344


637


674










EPOGEN®- U.S.

525


543


971


1,078










Sensipar®- U.S.

150


124


290


240










Mimpara®- ROW

82


75


161


146










Vectibix®- U.S.

31


31


62


61










Vectibix®- ROW

59


50


118


95










Nplate®- U.S.

50


40


104


77










Nplate®- ROW

36


35


72


63










XGEVA®- U.S.

156


73


295


115










XGEVA®- ROW

23


-


37


-










Prolia®- U.S.

75


30


129


47










Prolia®- ROW

45


14


79


24










Other - ROW

27


11


42


11











Total product sales

$  4,200


$  3,893


$  8,101


$  7,511



















U.S.

$  3,255


$  2,975


$  6,252


$  5,753










ROW

945


918


1,849


1,758











Total product sales

$  4,200


$  3,893


$  8,101


$  7,511

 

Amgen Inc.

Condensed Consolidated Balance Sheets - GAAP 

(In millions)

(Unaudited)












June 30, 


December 31, 





2012


2011

Assets





Current assets:





Cash, cash equivalents and marketable securities

$          22,475


$           20,641


Trade receivables, net

2,708


2,896


Inventories

2,592


2,484


Other current assets

1,787


1,572




Total current assets

29,562


27,593

Property, plant and equipment, net

5,437


5,420

Intangible assets, net

3,470


2,584

Goodwill


12,428


11,750

Other assets

1,329


1,524

Total assets

$          52,226


$           48,871








Liabilities and Stockholders' Equity




Current liabilities:





Accounts payable and accrued liabilities

$            5,616


$             5,670


Current portion of long-term debt

2,416


84




Total current liabilities

8,032


5,754

Long-term debt

21,962


21,344

Other non-current liabilities

2,993


2,744

Stockholders' equity

19,239


19,029

Total liabilities and stockholders' equity

$          52,226


$           48,871








Shares outstanding

769


796

 

Amgen Inc.

GAAP to "Adjusted" Reconciliations

(In millions)

(Unaudited)





















Three months ended


Six months ended 



June 30, 


June 30, 



2012


2011


2012


2011











GAAP cost of sales

$   682


$      602


$  1,361


$    1,166


Adjustments to cost of sales:









Incremental expense resulting from accelerating depreciation and/or accruing losses for facility operating
   leases as a result of our transaction with Boehringer Ingelheim involving our Fremont, California
   manufacturing facility

(11)


(23)


(21)


(44)


Acquisition-related expenses

-


(7)


-


(7)


Stock option expense (a)

(3)


(3)


(6)


(6)


Total adjustments to cost of sales

(14)


(33)


(27)


(57)


Adjusted cost of sales

$   668


$      569


$  1,334


$    1,109




















GAAP research and development expenses

$   826


$      819


$  1,562


$    1,555


Adjustments to research and development expenses:









Acquisition-related expenses

(13)


(1)


(20)


(25)


Stock option expense (a)

(6)


(10)


(12)


(19)


Total adjustments to research and development expenses

(19)


(11)


(32)


(44)


Adjusted research and development expenses

$   807


$      808


$  1,530


$    1,511




















GAAP selling, general and administrative expenses

$ 1,228


$   1,130


$  2,304


$    2,153


Adjustments to selling, general and administrative expenses:









Acquisition-related expenses

(22)


(6)


(34)


(8)


Stock option expense (a)

(7)


(13)


(14)


(23)


Total adjustments to selling, general and administrative expenses

(29)


(19)


(48)


(31)


Adjusted selling, general and administrative expenses

$ 1,199


$   1,111


$  2,256


$    2,122




















GAAP operating expenses

$ 2,888


$   2,627


$  5,459


$    5,040


Adjustments to operating expenses:









Adjustments to cost of sales

(14)


(33)


(27)


(57)


Adjustments to research and development expenses

(19)


(11)


(32)


(44)


Adjustments to selling, general and administrative expenses

(29)


(19)


(48)


(31)


Non-cash amortization of product technology rights acquired in a prior year business combination

(73)


(73)


(147)


(147)


Certain charges (or the reversal of certain previously over-accrued charges) pursuant to our continuing
   efforts to improve cost efficiencies in our operations

(69)


5


(70)


(11)


Expense resulting from changes in the estimated fair values of the contingent consideration
   obligations related to a prior year business combination

(1)


(3)


(3)


(3)


Expense related to certain legal proceedings

(9)


(5)


(12)


(5)


Total adjustments to operating expenses

(214)


(139)


(339)


(298)


Adjusted operating expenses

$ 2,674


$   2,488


$  5,120


$    4,742




















GAAP operating income

$ 1,589


$   1,332


$  3,066


$    2,625


Adjustments to operating expenses

214


139


339


298


Adjusted operating income

$ 1,803


$   1,471


$  3,405


$    2,923




















GAAP income before income taxes

$ 1,457


$   1,339


$  2,823


$    2,645


Adjustments to income before income taxes:









Adjustments to operating expenses

214


139


339


298


Non-cash interest expense associated with our convertible notes

35


32


69


76


Total adjustments to income before income taxes

249


171


408


374


Adjusted income before income taxes

$ 1,706


$   1,510


$  3,231


$    3,019




















GAAP provision for income taxes

$   191


$      169


$     373


$       350


Adjustments to provision for income taxes:









Income tax effect of the above adjustments (b)

82


60


138


125


Income tax benefit related to certain prior period charges excluded from "Adjusted" earnings

-


-


-


5


Total adjustments to provision for income taxes

82


60


138


130


Adjusted provision for income taxes

$   273


$      229


$     511


$       480




















GAAP net income

$ 1,266


$   1,170


$  2,450


$    2,295


Adjustments to income before income taxes, net of the tax effect of the above adjustments

167


111


270


249


Income tax benefit related to certain prior period charges excluded from "Adjusted" earnings

-


-


-


(5)


Adjusted net income

$ 1,433


$   1,281


$  2,720


$    2,539

 

Amgen Inc.


GAAP to "Adjusted" Reconciliations


(In millions, except per share data)


(Unaudited)























The following table presents the computations for GAAP and "Adjusted" diluted EPS, computed under the treasury stock method.


"Adjusted" EPS presented below excludes stock option expense:













Three months ended


Three months ended




June 30, 2012


June 30, 2011




GAAP


"Adjusted"  


GAAP


"Adjusted"  



Income (Numerator):










Net income for basic and diluted EPS

$     1,266


$     1,433


$    1,170


$    1,281













Shares (Denominator):










Weighted-average shares for basic EPS

776


776


927


927



Effect of dilutive securities

9


8

(*)

8


7

(*)


Weighted-average shares for diluted EPS

785


784


935


934













Diluted EPS

$      1.61


$       1.83


$      1.25


$      1.37














Six months ended 


Six months ended 




June 30, 2012


June 30, 2011




GAAP


"Adjusted" 


GAAP


"Adjusted" 



Income (Numerator):










Net income for basic and diluted EPS

$     2,450


$     2,720


$    2,295


$    2,539













Shares (Denominator):










Weighted-average shares for basic EPS

783


783


930


930



Effect of dilutive securities

9


8

(*)

8


7

(*)


Weighted-average shares for diluted EPS

792


791


938


937













Diluted earnings per share

$      3.09


$       3.44


$      2.45


$      2.71













(*)  Dilutive securities used to compute "Adjusted" diluted EPS for the three and six months ended June 30, 2012 and 2011 were computed under the treasury stock method assuming that we do not expense stock options.











(a)

For the three and six months ended June 30, 2012 and 2011, the total pre-tax expense for employee stock options was $16 million and $32 million, respectively and $26 million and $48 million, respectively.












"Adjusted" diluted EPS including the impact of stock option expense for the three and six months ended June 30, 2012 and 2011 was as follows: 














Three months ended


Six months ended 




June 30, 


June 30, 




2012


2011


2012


2011













"Adjusted" diluted EPS, excluding stock option expense

$      1.83


$       1.37


$      3.44


$      2.71













Impact of stock option expense (net of tax)

(0.01)


(0.02)


(0.03)


(0.04)













"Adjusted" diluted EPS, including stock option expense

$      1.82


$       1.35


$      3.41


$      2.67












(b)

The tax effect of the adjustments between our GAAP and "Adjusted" results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including amortization of intangible assets and non-cash interest expense associated with our convertible notes, whereas the tax impact of other adjustments, including stock option expense, depends on whether the amounts are deductible in the tax jurisdictions where the expenses are incurred or the asset is located and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three and six months ended June 30, 2012 and 2011 were 32.9% and 33.8% and 35.1% and 33.4%, respectively.











 

Amgen Inc.

Reconciliation of GAAP Debt Outstanding to "Adjusted" Debt Outstanding

(In millions)

(Unaudited)























GAAP


Adjustments for

accounting

standard (a)


"Adjusted"











June 30, 2011


$           13,930


$                  221


$           14,151


June 30, 2012


$           24,378


$                    84


$           24,462











(a)

To exclude the impact of bifurcating the debt and equity components of our convertible notes as required by U.S. accounting standards for these securities commencing in 2009.






 

Reconciliation of Free Cash Flow

(In millions)

(Unaudited)








Three months ended



June 30, 



2012


2011


Cash Flows from Operations

$     2,375


$     1,536


Capital Expenditures

(172)


(123)


Free Cash Flow

$     2,203


$     1,413

 

Amgen Inc.
Reconciliation of GAAP EPS Guidance to "Adjusted"
EPS Guidance for the Year Ending December 31, 2012
(Unaudited)


















2012




















GAAP EPS (diluted) guidance

a.

$   5.60

-

$   5.76




















Known adjustments to arrive at "Adjusted" earnings*:













Amortization of certain acquired intangible assets

(a)

0.24











Non-cash interest expense associated with our convertible notes

(b)

0.11











Charges associated with cost savings initiatives

(c)

0.10











Acquisition-related expenses

(d)

0.08











Stock option expense

(e)

0.06

-

0.05









Legal settlements

(f)

0.01






















"Adjusted" EPS (diluted) guidance

a.

$   6.20

-

$   6.35





















*


The known adjustments are presented net of their related aggregate tax impact of approximately $0.31 to $0.32 per share. 














(a)


To exclude the non-cash amortization of product technology rights acquired in a prior year business combination.














(b)


To exclude the non-cash interest expense associated with our convertible notes.
















(c)


To exclude certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations.














(d)


To exclude acquisition-related expenses.














(e)


To exclude stock option expense.














(f)


To exclude the expenses related to certain legal proceedings.















Reconciliation of GAAP Tax Rate Guidance to "Adjusted" 




Tax Rate Guidance for the Year Ending December 31, 2012







(Unaudited)









































2012 with PR excise tax


2012 without PR excise tax














GAAP tax rate guidance


11.2%

-

12.3%



17.0%

-

18.1%
















Tax rate effect of known adjustments discussed above


2.8%

-

2.7%



2.0%

-

1.9%















"Adjusted" tax rate guidance


14.0%

-

15.0%



19.0%

-

20.0%















(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

 

SOURCE Amgen